Peter Greenberg

Publications

• Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL, Schrier SL, Park CY, Weissman IL. Proc Natl Acad Sci U S A. 2013; 110 (8): 3011-6
• Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, Advani RH. J Clin Oncol. 2013; 31 (5): 592-8
• Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow Flores-Figueroa E, Varma S, Montgomery K, Greenberg P, Gratzinger D. Lab Investigation. 2012: 92 1330-1341
• Molecular and genetic features of myelodysplastic syndromes. Greenberg PL, Int J Lab Hematol. 2012; 34 (3): 215-22
• Personal omics profiling reveals dynamic molecular and medical phenotypes. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, Greenberg PL, Snyder P, Klein TE, Altman RB, Butte AJ, Ashley EA, Gerstein M, Nadeau KC, Tang H, Snyder M. Cell. 2012; 148 (6): 1293-307
• Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes. Raval A, Sridhar KJ, Patel S, Turnbull BB, Greenberg PL, Mitchell BS. Blood. 2012; 120 (24): 4812-8
• Revised international prognostic scoring system for myelodysplastic syndromes. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Blood. 2012; 120 (12): 2454-65
• Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Leuk Res. 2012; 36 (1): 98-103
• Myelodysplastic syndromes: dissecting the heterogeneity. Greenberg PL, J Clin Oncol. 2011; 29 (15): 1937-8
• NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P. J Natl Compr Canc Netw. 2011; 9 (1): 30-56
• Current therapeutic approaches for patients with myelodysplastic syndromes. Greenberg PL, Br J Haematol. 2010; 150 (2): 131-43
• Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C. Leuk Res. 2010; 34 (12): 1560-5
• A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL. Am J Hematol. 2009; 84 (1): 15-20
• NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes Greenberg, PL, Rigsby C, Stone RM, Deeg J, Gore S, Millenson M, Nimer S, O'Donnell M, Shami P, Kumar R. J Nat Comp Cancer Network. 2009; 7 ((Suppl 9): S1-16
• Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL. Blood. 2009; 114 (23): 4847-58
• Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM. Blood. 2009; 114 (12): 2393-400
• Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. Sloand EM, Wu C, Greenberg P, et al. J Clin Oncol. 2008: 26 2505-2511
• International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome Kao JM, McMillan A, Greenberg PL. Am J Hematology. 2008
• Myelodysplastic syndromes. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P. J Natl Compr Canc Netw. 2008; 6 (9): 902-26
• Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q. Raza A, Reeves JE, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, et al. Blood. 2008: 111 86-93
• Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF Park S, Grabar S, Kelaidi C, Greenberg P, et al.. Blood. 2008: 111 574-582
• Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study. Porter J, Galanello R, Saglio S,Greenberg P, et al. Eur J Haematol. 2008: 80 168-176
• The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Greenberg PL, Cosler LE, Ferro SA, Lyman GH. J Natl Compr Canc Netw. 2008; 6 (9): 942-53
• Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Leukemia Research. 2007: 31 727-736
• Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods Kao JM, Greenberg PL. Clinical Leukemia. 2007: 1 172-182
• A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia Lancet J, Gojo I, Gotlib J, Greenberg PL, et al. Blood. 2006: 108 1387-1394
• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Cheson BD, Greenberg PL, Bennett JM, et al. Blood. 2006: 108 419-425
• Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, et al. New Eng J Med. 2006: 355 1456-1465
• Myelodysplastic Syndromes: Clinical and Biological Advances Greenberg, PL, Editor, Cambridge University Press, Cambridge, England. 2006
• Myelodysplastic syndromes clinical practice guidelines in oncology. Greenberg PL, Baer MR, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Devetten MP, Emanuel PD, Erba HP, Estey E, Foran J, Gore SD, Millenson M, Navarro WH, Nimer SD, O'Donnell MR, Saba HI, Spiers K, Stone RM, Tallman MS. J Natl Compr Canc Netw. 2006; 4 (1): 58-77
• Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Greenberg PL, J Natl Compr Canc Netw. 2006; 4 (1): 91-6
• Management of patients with higher risk myelodysplastic syndromes. Fukumoto JS, Greenberg PL. Crit Rev Oncol Hematol. 2005; 56 (2): 179-92
• A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome Cutler C,, Lee SJ, Greenberg P, et al. Blood. 2004: 104 579-585
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. J Clin Oncol. 2004; 22 (6): 1078-86
• Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Cherry AM, Brockman SR, Paternoster SF, Hicks GA, Neuberg D, Higgins RR, Bennett JM, Greenberg PL, Miller K, Tallman MS, Rowe J, Dewald GW. Leuk Res. 2003; 27 (12): 1085-90
• Novel biospecific agents for the treatment of myelodysplastic syndromes. Gotlib J, Greenberg P. J Nat Comprehensive Cancer Network. 2003: 1 473-480
• Myelodysplastic syndromes. Greenberg PL, Young NS, Gattermann N. Hematology Am Soc Hematol Educ Program. 2002: 136-61
• Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. Greenberg P, Lancet. 2001; 357 (9262): 1059-60
• Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. Greenberg P, Ann Rheum Dis. 2001: 60 Suppl 3 iii41-2
• The Myelodysplastic Syndromes , . Greenberg PL, Hematology: Basic Principles and Practice. 3rd Ed., Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, Eds. Churchill Livingstone, NY,. 2000: 1106-1129
• Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Greenberg PL, Sanz GF, Sanz MA. Forum (Genova). 1999 Jan-Mar; 9 (1): 17-31
• Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Greenberg PL, Leuk Res. 1998; 22 (12): 1123-36
• Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Davis RE, Greenberg PL. Leuk Res. 1998; 22 (9): 767-77
• NCCN Practice Guidelines for Myelodysplastic Syndromes Greenberg PL, Bishop M, Deeg J, Erba H, Gore S, Nimer S, O’Donnell M, Tallman M, Bennett J, Estey E, Stone R. Oncology. 1998; 12 (11A): 53-80
• Risk factors and their relationship to prognosis in myelodysplastic syndromes. Greenberg PL, Leuk Res. 1998: 22 Suppl 1 S3-6
• International scoring system for evaluating prognosis in myelodysplastic syndromes. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. Blood. 1997; 89 (6): 2079-88
• Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Blood. 1996; 88 (11): 4275-87
• Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Greenberg PL, Semin Hematol. 1996; 33 (2): 163-75
• GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C. Bone Marrow Transplant. 1996; 18 (6): 1057-64
• Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL. Blood. 1996; 87 (10): 4076-81
• Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes. Nagler A, MacKichan ML, Negrin RS, Donlon T, Greenberg PL. Leukemia. 1995; 9 (1): 30-9
• Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation. Schriber JR, Dejbakhsh-Jones S, Kusnierz-Glaz CR, Ginzton N, Still B, Negrin RS, Greenberg P, Strober S. Exp Hematol. 1995; 23 (9): 1024-9
• Modulation of apoptosis in human myeloid leukemic cells by GM-CSF. Han JH, Gileadi C, Rajapaksa R, Kosek J, Greenberg PL. Exp Hematol. 1995; 23 (3): 265-72
• Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL. Blood. 1993; 82 (3): 737-43
• In vitro marrow culture studies in the myelodysplastic syndromes. Greenberg PL, Semin Oncol. 1992; 19 (1): 34-46
• Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size Greenberg PL, --. 1992
• T-cell subsets and suppressor cells in human bone marrow. Schmidt-Wolf IG, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S. Blood. 1992; 80 (12): 3242-50
• Treatment of myelodysplastic syndromes with hemopoietic growth factors. Greenberg PL, Semin Oncol. 1992; 19 (1): 106-14
• Effects of insulin-like growth factors on hemopoiesis. Greenberg PL, Blood Cells. 1991; 17 (2): 344-6; discussion 347-8
• Treatment of myelodysplastic syndromes. Greenberg PL, Blood Rev. 1991; 5 (1): 42-50
• Bone marrow cell modulation and inhibition of myelopoiesis by large granular lymphocytes and natural killer cells. Nagler A, Greenberg PL. Int J Cell Cloning. 1990; 8 (3): 171-83
• Effects of CSFs in preleukemia. Greenberg PL, Negrin R, Nagler A. Bone Marrow Transplant. 1990: 6 Suppl 1 121-6
• Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Greenberg P, Negrin R, Nagler A, Vincent M, Donlon T. Int J Cell Cloning. 1990: 8 Suppl 1 293-300; discussion 300-2
• Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Nagler A, Ginzton N, Negrin R, Bang D, Donlon T, Greenberg P. Leukemia. 1990; 4 (3): 193-202
• Functional interactions between colony-stimulating factors and the insulin family hormones for human myeloid leukemic cells. Oksenberg D, Dieckmann BS, Greenberg PL. Cancer Res. 1990; 50 (20): 6471-7
• Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Lewinsohn DM, Nagler A, Ginzton N, Greenberg P, Butcher EC. Blood. 1990; 75 (3): 589-95
• Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Nagler A, Binet C, Mackichan ML, Negrin R, Bangs C, Donlon T, Greenberg P. Blood. 1990; 76 (7): 1299-307
• Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL. Blood. 1990; 76 (1): 36-43
• Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Negrin RS, Haeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, Greenberg PL. Ann Intern Med. 1989; 110 (12): 976-84
• Selective generation of erythroid burst-promoting activity by recombinant interleukin 2-stimulated human T lymphocytes and natural killer cells. Skettino S, Phillips J, Lanier L, Nagler A, Greenberg P. Blood. 1988; 71 (4): 907-14
• Biologic nature of the myelodysplastic syndromes. Greenberg PL, Acta Haematol. 1987: 78 Suppl 1 94-9
• Receptor binding and mitogenic effects of insulin and insulinlike growth factors I and II for human myeloid leukemic cells. Pepe MG, Ginzton NH, Lee PD, Hintz RL, Greenberg PL. J Cell Physiol. 1987; 133 (2): 219-27